financetom
Business
financetom
/
Business
/
Looking At Citigroup's Recent Unusual Options Activity
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Looking At Citigroup's Recent Unusual Options Activity
Jul 8, 2025 7:29 AM

Investors with a lot of money to spend have taken a bullish stance on Citigroup ( C ) .

And retail traders should know.

We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with C, it often means somebody knows something is about to happen.

So how do we know what these investors just did?

Today, Benzinga's options scanner spotted 16 uncommon options trades for Citigroup ( C ).

This isn't normal.

The overall sentiment of these big-money traders is split between 68% bullish and 31%, bearish.

Out of all of the special options we uncovered, 2 are puts, for a total amount of $203,581, and 14 are calls, for a total amount of $12,929,590.

Predicted Price Range

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $60.0 and $87.5 for Citigroup ( C ), spanning the last three months.

Volume & Open Interest Development

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.

This data can help you track the liquidity and interest for Citigroup's ( C ) options for a given strike price.

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Citigroup's ( C ) whale activity within a strike price range from $60.0 to $87.5 in the last 30 days.

Citigroup Option Activity Analysis: Last 30 Days

Significant Options Trades Detected:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
C CALL SWEEP BEARISH 06/17/27 $21.25 $20.4 $20.5 $75.00 $11.0M 7.8K 7.3K
C CALL SWEEP BULLISH 06/17/27 $20.65 $20.4 $20.65 $75.00 $687.6K 7.8K 1.5K
C CALL SWEEP BULLISH 06/17/27 $20.75 $20.7 $20.75 $75.00 $456.5K 7.8K 214
C CALL SWEEP BULLISH 06/17/27 $20.65 $20.6 $20.65 $75.00 $212.7K 7.8K 1.9K
C PUT SWEEP BULLISH 01/16/26 $4.85 $4.8 $4.81 $82.50 $146.7K 2.5K 165

About Citigroup

Citigroup ( C ) is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's ( C ) operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.

In light of the recent options history for Citigroup ( C ), it's now appropriate to focus on the company itself. We aim to explore its current performance.

Current Position of Citigroup

Trading volume stands at 1,075,211, with C's price down by -0.68%, positioned at $87.0.

RSI indicators show the stock to be may be overbought.

Earnings announcement expected in 7 days.

Professional Analyst Ratings for Citigroup

A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $91.8.

Turn $1000 into $1270 in just 20 days?

20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.

* Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on Citigroup ( C ) with a target price of $94.

* An analyst from B of A Securities has decided to maintain their Buy rating on Citigroup ( C ), which currently sits at a price target of $100.

* An analyst from Goldman Sachs persists with their Buy rating on Citigroup ( C ), maintaining a target price of $85.

* An analyst from Evercore ISI Group persists with their In-Line rating on Citigroup ( C ), maintaining a target price of $77.

* An analyst from Morgan Stanley has decided to maintain their Overweight rating on Citigroup ( C ), which currently sits at a price target of $103.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Citigroup ( C ) options trades with real-time alerts from Benzinga Pro.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Avenue Therapeutics (ATXI) Stock Is Falling Sharply
Why Avenue Therapeutics (ATXI) Stock Is Falling Sharply
Apr 29, 2024
Avenue Therapeutics ( ATXI ) shares are trading lower by 20.7% to $4.92 during Monday’s session after the company announced the exercise of warrants for $4.4 million in gross proceeds. These warrants were issued at different times with various exercise prices, but the warrant holders have agreed to exercise them at a reduced price of $6.20 per share. The company...
Why SINTX Technologies Shares Are Skyrocketing
Why SINTX Technologies Shares Are Skyrocketing
Apr 29, 2024
SINTX Technologies Inc ( SINT ) shares are trading higher by 32% to $0.05 during Monday’s session after the company and Prodways Printers announced they have entered into a technical partnership and ceramic slurry supply agreement. Under this collaboration, SINTX ( SINT ) and its subsidiary will provide ceramic-filled printable slurries to Prodways and aid in process development and customer...
AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed
AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed
Apr 29, 2024
10:56 AM EDT, 04/29/2024 (MT Newswires) -- AIM ImmunoTech ( AIM ) said Monday that the safety evaluation of patients in the first dose level of a phase 1b/2 trial of the combination of Ampligen, or rintatolimod, and AstraZeneca's ( AZN ) Imfinzi, or durvalumab, in late-stage pancreatic cancer has been completed. The evaluation, conducted by investigators at Erasmus Medical...
Sonoco Increasing Prices of Tubes, Cores in Mexico
Sonoco Increasing Prices of Tubes, Cores in Mexico
Apr 29, 2024
10:57 AM EDT, 04/29/2024 (MT Newswires) -- Sonoco Products ( SON ) said Monday that it is increasing the prices of tubes and cores products sold in Mexico by 6%, starting with deliveries in May. The price increase is due to inflationary pressures and higher basic raw material costs, said Jose Villafana, vice president and general manager for paper products...
Copyright 2023-2026 - www.financetom.com All Rights Reserved